Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1612 1641 1643 1644
This examiner grants 53% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17595671 | COMBINATION THERAPY | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 18154262 | VERRUCARIN A DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17423796 | Glycoside-Containing Peptide Linkers for Antibody-Drug Conjugates | Non-Final OA | R.P. Scherer Technologies, LLC |
| 17431270 | USE OF PLASMA MEMBRANE PARTICLES, LIPOSOMES, AND EXOSOMES TO ASSAY IMMUNE CELL POTENCY | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 17598780 | NUCLEAR-DERIVED EXOSOMES AND METHODS OF USE THEREOF | Final Rejection | Board of Regents, The University of Texas System |
| 17997137 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | Non-Final OA | Novartis AG |
| 18557988 | RADIOIMMUNOCONJUGATES DIRECTED TO NKG2D LIGANDS FOR THE TREATMENT OF CANCER | Non-Final OA | ACTINIUM PHARMACEUTICALS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy